Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes
Conditions
Acute Coronary Syndrome
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Novartis Investigative Site, Clayton, Victoria, Australia
Novartis Investigative Site, Montreal, Quebec, Canada
Novartis Investigative Site, Beijing, China, China
Novartis Investigative Site, Guangzhou, Guangdong, China
Novartis Investigative Site, Luoyang, Henan, China
Novartis Investigative Site, Xuzhou, Jiangsu, China
Novartis Investigative Site, Nanchang, Jiangxi, China
Novartis Investigative Site, Wenzhou, Zhejiang, China
Novartis Investigative Site, Beijing, China
Novartis Investigative Site, Beijing, China
Novartis Investigative Site, Guangzhou, China
Novartis Investigative Site, Guangzhou, China
Novartis Investigative Site, Jining, China
Novartis Investigative Site, Shanghai, China
Novartis Investigative Site, Shanghai, China
Novartis Investigative Site, Tianjin, China
Novartis Investigative Site, Chambray-lès-Tours, France
Novartis Investigative Site, Montpellier, France
Novartis Investigative Site, Nantes, France
Novartis Investigative Site, Pessac, France
Novartis Investigative Site, Poitiers, France
Novartis Investigative Site, Leipzig, Saxony, Germany
Novartis Investigative Site, Coburg, Germany
Novartis Investigative Site, Erfurt, Germany
Novartis Investigative Site, Essen, Germany
Novartis Investigative Site, Hennigsdorf, Germany
Novartis Investigative Site, Kiel, Germany
Novartis Investigative Site, Hong Kong, Hong Kong, Hong Kong
Novartis Investigative Site, Hong Kong, Hong Kong
Novartis Investigative Site, Pécs, Baranya, Hungary
Novartis Investigative Site, Debrecen, Hajdu Bihar Megye, Hungary
Novartis Investigative Site, Budapest, Hungary
Novartis Investigative Site, Budapest, Hungary
Novartis Investigative Site, Miskolc, Hungary
Novartis Investigative Site, Belagavi, Karnataka, India
Novartis Investigative Site, Mumbai, Maharashtra, India
Novartis Investigative Site, Nashik, Maharashtra, India
Novartis Investigative Site, Bikaner, Rajasthan, India
Novartis Investigative Site, Chikushino-shi, Fukuka, Japan
Novartis Investigative Site, Kitakyushu, Fukuoka, Japan
Novartis Investigative Site, Kamakura, Kanagawa, Japan
Novartis Investigative Site, Sagamihara, Kanagawa, Japan
Novartis Investigative Site, Bunkyo Ku, Tokyo, Japan
Novartis Investigative Site, Gdansk, Poland
Novartis Investigative Site, Krakow, Poland
Novartis Investigative Site, Opole, Poland
Novartis Investigative Site, Seoul, Seoul, South Korea
Novartis Investigative Site, Seoul, South Korea
Novartis Investigative Site, Santiago Compostela, A Coruna, Spain
Novartis Investigative Site, Huelva, Andalusia, Spain
Novartis Investigative Site, El Palmar, Murcia, Spain
Novartis Investigative Site, Las Palmas GC, Spain
Novartis Investigative Site, Madrid, Spain
Novartis Investigative Site, Madrid, Spain
Novartis Investigative Site, Salamanca, Spain
Novartis Investigative Site, Seville, Spain
Novartis Investigative Site, Valencia, Spain
Novartis Investigative Site, Bern, Switzerland
Novartis Investigative Site, Geneva, Switzerland
Novartis Investigative Site, Lucerne, Switzerland
Study leads
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals